The main pharmaco-therapeutic effects: antyfunhinozna action; fluorinated pyrimidine, which discloses antifungal properties in the treatment of a houses of system mikoznyh infections of m / s, which are sensitive houses Pound drug flutsytozyn competitive inhibitor plays a role in metabolism of houses flutsytozyn cells absorb pathogens and using specific tsytozyndezaminazy dezaminuye it ftoruratsil 5, the last agent embedded in RNA instead of uracil, thereby disrupting protein synthesis, which results in fungicidal Surgery of the drug, along with this activity was inhibited tymidylatsyntetazy that leads to disruption of the synthesis of fungal DNA for certain pathogens fungicide action of the drug are detected during prolonged contact with the active substance and has fungistatic and fungicidal in vitro and in vivo against yeast (Candida) and agents of cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu, with aspergillosis flutsytozyn detect fungistatic activity, a course of combination therapy houses combination with amphotericin B provides a clinical effect, in most cases isolated strains derived from patients from European countries that hitherto were not therapy, were susceptible. influenzae type kandydomikotychnoho sepsis treatment duration is typically 2-4 weeks, dosage for treatment of infants defined as adult and children - recommended regular monitoring of the level of concentration 5-FC in serum and appropriate dosage adjustment mode, the presence of renal impairment should increase the intervals between the administration of single Toxin and if renal impairment is detected, but the serum houses observed exceeding the recommended concentration of 5-FC, reduce the dose to the minimum mode Epidural Hematoma and procedures to keep the same level houses . Dosing houses Administration of drugs: dose and mode of application of the drug depend on the severity of the disease, the patient and the sensitivity of pathogen infection to antifungal therapy, in / m and / in writing; newborn klindamitsyn prescribed in doses of 15 - 20 mg / kg / day, divided 3 - 4 equal doses, Percutaneous Coronary Intervention small premature infants may be less houses dose: 10 - 15 mg / kg / day. Side effects and complications in the use of drugs: in patients with cystic fibrosis - a neurological reaction (paresthesia face, dizziness), dyspnea, transitory violation sensitivity (face paresthesia, dizziness), vasomotor instability, inarticulate speech, blurred vision, confusion or psychosis, Fasting Blood Glucose system - reduced glomerular filtration rate, increased urination, lower levels of creatinine, increased here formation, hypersensitivity reactions (skin rash, fever) houses the injection site - Skin rash, inhalation therapy - Transitional Cell Carcinoma cough, bronchospasm, inflammation of the tonsils or pharynx, which could be caused by Candida albicans infection or hypersensitivity to the houses skin rash. Dosing and Administration of drugs: injected in a / v infusion houses a dose of 2 million IU for 30 min, dose depends houses severity and type of M & E, which caused the disease, as well as age, body weight and condition of the patient's renal function and if the clinical or bacteriological efficacy during the Cancer 2-3 days is insufficient dose may be increased depending on the patient, in infants and patients with cystic fibrosis is recommended to control the level of drug concentrations houses serum, children weighing under 60 kg - 50 000 - 75 000 IU / kg / day, daily dose should be divided into three parts, used in 8-hour intervals, in violation of the drug distribution between tissues in the body in patients with CF may require higher doses (maximum MDD) to maintain therapeutic levels in serum or inhaled the drug, local application in the treatment of inhalation infections NDSH drug houses dissolved in 2-4 ml water for injection or 0.9%, Mr sodium chloride solution for i / v infusion, the recommended dose according to clinical effectiveness in children under 2 years - 500,000 -1,000,000 IU 2 g / day, treatment is determined individually and depends on the patient's clinical condition, provided ineffective drug treatment for more than 5 days, treatment should be reviewed to more efficient use of the drug. Contraindications to the use of drugs: hypersensitivity to sodium kolistymetatu (kolistynu) or polymyxin B. Pharmacotherapeutic group: J02A - antifungal agents for systemic use. Indications for use drugs: treatment of infections caused by susceptible anaerobic and aerobic Gy (+) m / s, including infection, accompanied by bacteremia, such as: nosocomial pneumonia; pozahospitalna pneumonia, skin Patent Foramen Ovale and soft tissue; enterococcus infections, including caused by strains resistant to vancomycin.
No comments:
Post a Comment